

Firm News | May 9, 2022

Troutman Pepper Advises Apnimed in Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea and Related Sleep Disorders

RELATED PROFESSIONALS

Christopher S. Miller | Daniel R. Sieck | Stephen M. Fox | Michael J. Crumbock | Tracey E. Diamond | Judith L. O'Grady | Sean P. McConnell | Noreen Hibbard Onimus | Callan G. Stein | Angelo A. Stio, III | Joseph A. Goldman | Timothy C. Atkins | Kimberly Hughes Gillespie

RELATED OFFICES

Washington, D.C. | Philadelphia | Boston | Berwyn

BOSTON – Troutman Pepper client Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, has raised \$62.5 million of committed capital in a Series C financing. New investor, Sectoral Asset Management, led the round. Also participating were new investors Alpha Wave Ventures, NexPoint, and others, joining existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners. Read a company press release about the financing.

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed's lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.

The Troutman Pepper team advising Apnimed includes Chris Miller, Daniel Sieck, Stephen Fox, Jake McDonough, Joseph Goldman, Timothy Atkins, Michael Crumbock, Tracey Diamond, Kimberly Gillespie, Judith O'Grady, Sean McConnell, Noreen Onimus, Callan Stein, and Angelo Stio, among others.

Apnimed has been a member of Troutman Pepper's Startup and Early-Stage Entrepreneurial Development (SEED) Program since the company's inception. The program combines the resources of an experienced, multidisciplinary team into an affordable package for startups, early-stage, and fast-growing companies. Clients receive legal counsel, mentoring, relationship building opportunities, and more.

The firm regularly advises startup, emerging growth and venture capital clients through every stage of their life cycle. Industries served span software, hardware and other high-technology, biotechnology, pharmaceuticals and medical devices, financial technology, health care, consumer products, food and beverage, media and telecommunications products and services, and many others.

Visit seed.troutman.com to learn more about Troutman Pepper's SEED program.

About Troutman Pepper

Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm's litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients' most pressing business challenges, with depth across industry sectors, including energy, financial services, health sciences, insurance, and private equity, among others. Learn more at troutman.com.

RELATED INDUSTRIES + PRACTICES

- Corporate
- Emerging Companies + Venture Capital
- Health Care + Life Sciences
- Labor + Employment